Publication Name	World Journal of Gastroenterology
Manuscript ID	6278
Country	Hungary

Received	2013-10-11 20:36
Peer-Review Started	2013-10-12 14:11
First Decision by Editorial Office Director
Return for Revision	2013-11-01 11:41
Revised	2013-12-13 04:18
Publication Fee Transferred
Second Decision by Editor	2014-01-08 18:13
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2014-01-08 18:40
Articles in Press
Edit the Manuscript by Language Editor	2014-04-14 21:45
Typeset the Manuscript	2014-04-30 08:08
Publish the Manuscript Online	2014-05-07 10:10

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Autobiography
Article Title	Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease
Manuscript Source	Invited Manuscript
All Author List	Éva Pallagi-Kunstár, Klaudia Farkas, Zoltán Szepes, Ferenc Nagy, Mónika Szűcs, Róbert Kui, Rolland Gyulai, Anita Bálint, Tibor Wittmann and Tamás Molnár
Funding Agency and Grant Number	Funding Agency Grant Number TAMOP-4.2.2.A-11/1/KONV 2012-0035 TAMOP-4.2.2-A-11/1/KONV 2012-0052 TAMOP-4.2.2.A-11/1/KONV 2012-0073 OTKA Research Proposal PD 105948
Corresponding Author	amás Molnár, MD, PhD, First Department of Medicine, University of Szeged, Korányi fasor 8-10, H6720 Szeged, Hungary. molnar.tamas@med.u-szeged.hu
Key Words	Tumor necrosis factor-α; Infliximab; Antibody; Inflammatory bowel disease
Core Tip	The clinical utility of measuring serum tumor necrosis factor-α (TNF-α), infliximab, and anti-infliximab levels in the therapeutic decisions of patients with inflammatory bowel disease is still an outstanding question. In this study we assessed TNF-α, infliximab concentrations, and antibodies against infliximab molecules in patients with inflammatory bowel disease who developed loss of response, side effects, or allergic reaction during anti TNF-α therapy. Our results showed that the simultaneous measurement of serum TNF-α level, serum anti TNF-α concentration, and antibodies against anti TNF-α may further help to optimize therapy in critical situations.
Publish Date	2014-05-07 10:10
Citation	Pallagi-Kunstár É, Farkas K, Szepes Z, Nagy F, Szűcs M, Kui R, Gyulai R, Bálint A, Wittmann T, Molnár T. Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease. World J Gastroenterol 2014; 20(17): 5031-5035
URL	http://www.wjgnet.com/1007-9327/full/v20/i17/5031.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i17.5031

Full Article (PDF)	WJG-20-5031.pdf
Full Article (Word)	WJG-20-5031.doc
Manuscript File	6278-Review.doc
Answering Reviewers	6278-Answering reviewers.pdf
Copyright License Agreement	6278-Copyright assignment.pdf
Peer-review Report	6278-Peer review(s).pdf